Printer Friendly

Colon Screening Falls Short.

The combination of fecal occult blood testing and sigmoidoscopy failed to identify one-quarter of asymptomatic people with advanced neoplasia and one-half of those with advanced lesions in the proximal colon, said Dr. David A. Lieberman and David C. Weiss, Ph.D., of the Veterans Affairs Cooperative Study Group 380.

Rehydrated fecal occult blood tests (FOBTs) and colonoscopy were performed on 2,885 asymptomatic men. The investigators used examination of the rectum and sigmoid colon during colonoscopy as a surrogate for sigmoidoscopy.

Advanced neoplasia was found in 306 men (11%)--182 lesions were in the distal colon and 150 were in the proximal colon, with some overlap between the two in the remaining 74. One-time FOBT plus sigmoidoscopy was able to detect advanced neoplasia in 76% of the men examined (N. Engl. J. Med. 8345[8]:555-60, 2001).

Of the 150 men with lesions in the proximal colon, combined one-time FOBT and sigmoidoscopy would have identified 76 patients (51%).
COPYRIGHT 2001 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:fecal occult blood testing and sigmoidoscopy misses 25% of tumors in testing
Author:Kubetin, Sally Koch
Publication:Internal Medicine News
Article Type:Brief Article
Geographic Code:1USA
Date:Oct 1, 2001
Words:158
Previous Article:H. pylori No Impact on BP.
Next Article:Celiac Disease Mortality.
Topics:


Related Articles
Colorectal Cancer Screening. (Guest Editorial).
Reminder program helps follow-up on positive FOBTs. (Improved Ordering of Further Studies).
Strong federal backing for colorectal cancer screening. (Five Options Cited as Acceptable).
Colon ca screening practices are often deficient.
Colon Cancer; Prevention.
Colon exams follow abnormal stool tests only half the time.
Fecal occult blood testing no longer advised.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |